Artiva Biotherapeutics, Inc.
ARTV · XNASCIK 1817241fmd_0NPDZCCC4ZCA4HYSBQ47F1T179Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 33 | 0 | 0 |
| Research and development | 50 | 50 | 70 |
| Total operating expenses | 64 | 68 | 90 |
| Operating income | (31) | (67) | (90) |
| Other non-operating income (expense) | 2 | 2 | 6 |
| Income before taxes | (29) | (65) | – |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (29) | (65) | – |
| Net income | (29) | (65) | (84) |